ABIVAX Société Anonyme (ABVX)
NASDAQ: ABVX · Real-Time Price · USD
6.25
-0.18 (-2.80%)
Mar 31, 2025, 4:00 PM EDT - Market closed
Company Description
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases.
The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
ABIVAX Société Anonyme
| Country | France |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 61 |
| CEO | Marc M. de Garidel |
Contact Details
Address: 7-11 boulevard Haussmann Paris, 75009 France | |
| Phone | 33 1 53 83 09 63 |
| Website | abivax.com |
Stock Details
| Ticker Symbol | ABVX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $11.60 |
| CIK Code | 0001956827 |
| CUSIP Number | 00370M103 |
| ISIN Number | US00370M1036 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Marc M. P. de Garidel M.B.A. | Chief Executive Officer and Director |
| Didier Blondel | EVice President, Chief Financial Officer and Board Secretary |
| Didier Scherrer Ph.D. | Chief Scientific Officer |
| Patrick Malloy | Senior Vice President of Investor Relations |
| Ida Hatoum | Chief People and Compliance Officer |
| Pierre Courteille M.B.A. | Chief Business Officer |
| Jerome Denis Ph.D. | Executive Vice President of Process Development and Manufacturing |
| Ana Sharma M.P.H. | Vice President and Global Head of Quality |
| Hema Keshava | Senior Vice President of Finance |
| Chris Rabbat Ph.D. | Vice President and Global Head of Medical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 24, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 24, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Mar 24, 2025 | 6-K | Report of foreign issuer |
| Feb 14, 2025 | SCHEDULE 13D/A | Filing |
| Jan 10, 2025 | 6-K | Report of foreign issuer |
| Dec 23, 2024 | 6-K | Report of foreign issuer |
| Nov 26, 2024 | EFFECT | Notice of Effectiveness |
| Nov 22, 2024 | UPLOAD | Filing |
| Nov 19, 2024 | 6-K | Report of foreign issuer |
| Nov 19, 2024 | F-3 | Filing |